» Articles » PMID: 28151411

Immunologic Effects of the Renin-Angiotensin System

Overview
Specialty Nephrology
Date 2017 Feb 3
PMID 28151411
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Inappropriate activation of the renin-angiotensin system (RAS) exacerbates renal and vascular injury. Accordingly, treatment with global RAS antagonists attenuates cardiovascular risk and slows the progression of proteinuric kidney disease. By reducing BP, RAS inhibitors limit secondary immune activation responding to hemodynamic injury in the target organ. However, RAS activation in hematopoietic cells has immunologic effects that diverge from those of RAS stimulation in the kidney and vasculature. In preclinical studies, activating type 1 angiotensin (AT) receptors in T lymphocytes and myeloid cells blunts the polarization of these cells toward proinflammatory phenotypes, protecting the kidney from hypertensive injury and fibrosis. These endogenous functions of immune AT receptors temper the pathogenic actions of renal and vascular AT receptors during hypertension. By counteracting the effects of AT receptor stimulation in the target organ, exogenous administration of AT receptor agonists or angiotensin 1-7 analogs may similarly limit inflammatory injury to the heart and kidney. Moreover, although angiotensin II is the classic effector molecule of the RAS, several RAS enzymes affect immune homeostasis independently of canonic angiotensin II generation. Thus, as reviewed here, multiple components of the RAS signaling cascade influence inflammatory cell phenotype and function with unpredictable and context-specific effects on innate and adaptive immunity.

Citing Articles

A Five-Year Prospective, Randomized, Open-Label Study of Standard-Dose Versus Low-Dose Prolonged-Release Tacrolimus With or Without Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Post Kidney Transplantation.

Campbell P, Cantarovich M, Gangji A, Houde I, Jevnikar A, Monroy-Cuadros F Clin Transplant. 2024; 39(1):e70067.

PMID: 39739990 PMC: 11683858. DOI: 10.1111/ctr.70067.


Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.

Mazhar F, Faucon A, Fu E, Szummer K, Mathisen J, Gerward S Eur Heart J. 2024; 45(44):4719-4730.

PMID: 39211962 PMC: 11578643. DOI: 10.1093/eurheartj/ehae557.


Differential gene expression in the kidneys of SHR and WKY rats after intravenous administration of Akkermansia muciniphila-derived extracellular vesicles.

Olarinoye Z, Kim C, Kim J, Jang S, Kim I Sci Rep. 2024; 14(1):20056.

PMID: 39209875 PMC: 11362604. DOI: 10.1038/s41598-024-69757-x.


Lymphocytes and innate immune cells in acute kidney injury and repair.

Lee K, Jang H, Rabb H Nat Rev Nephrol. 2024; 20(12):789-805.

PMID: 39095505 DOI: 10.1038/s41581-024-00875-5.


Untargeted Metabolomic Analysis Reveals Plasma Differences between Mares with Endometritis and Healthy Ones.

Zhang X, Gao Y, Mai Z, Li Y, Wang J, Zhao X Animals (Basel). 2024; 14(13).

PMID: 38998045 PMC: 11240781. DOI: 10.3390/ani14131933.


References
1.
Akai Y, Sato H, Iwano M, Kurumatani N, Kurioka H, Kubo A . Association of an insertion polymorphism of angiotensin-converting enzyme gene with the activity of lupus nephritis. Clin Nephrol. 1999; 51(3):141-6. View

2.
Sabuhi R, Ali Q, Asghar M, Al-Zamily N, Hussain T . Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats. Am J Physiol Renal Physiol. 2011; 300(3):F700-6. PMC: 3064141. DOI: 10.1152/ajprenal.00616.2010. View

3.
Perez De Lema G, De Wit C, Cohen C, Nieto E, Molina A, Banas B . Angiotensin inhibition reduces glomerular damage and renal chemokine expression in MRL/lpr mice. J Pharmacol Exp Ther. 2003; 307(1):275-81. DOI: 10.1124/jpet.103.053678. View

4.
Curato C, Slavic S, Dong J, Skorska A, Altarche-Xifro W, Miteva K . Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. J Immunol. 2010; 185(10):6286-93. DOI: 10.4049/jimmunol.0903681. View

5.
Petty W, Miller A, McCoy T, Gallagher P, Tallant E, Torti F . Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res. 2009; 15(23):7398-404. PMC: 3703919. DOI: 10.1158/1078-0432.CCR-09-1957. View